Roivant Sciences Ltd. Files 8-K
Ticker: ROIV · Form: 8-K · Filed: Sep 3, 2025 · CIK: 1635088
Sentiment: neutral
Topics: 8-K, regulatory-filing, corporate-disclosure
TL;DR
Roivant Sciences filed an 8-K on 9/3/25 covering Reg FD, other events, and financials.
AI Summary
Roivant Sciences Ltd. filed an 8-K on September 3, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures, other events, and financial statements and exhibits. The company is incorporated in Bermuda with its principal executive offices located in London, United Kingdom.
Why It Matters
This 8-K filing provides updates on Roivant Sciences Ltd.'s corporate activities and regulatory disclosures, which are important for investors to monitor the company's compliance and operational status.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant negative news or events.
Key Players & Entities
- Roivant Sciences Ltd. (company) — Registrant
- September 3, 2025 (date) — Date of earliest event reported
- London (location) — Principal executive offices city
- United Kingdom (location) — Principal executive offices country
FAQ
What is the primary purpose of this 8-K filing for Roivant Sciences Ltd.?
The primary purpose is to report on Regulation FD disclosures, other events, and financial statements and exhibits as of September 3, 2025.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on September 3, 2025.
Where are Roivant Sciences Ltd.'s principal executive offices located?
Roivant Sciences Ltd.'s principal executive offices are located at 7th Floor, 50 Broadway, London, SW1H 0DB, United Kingdom.
What is Roivant Sciences Ltd.'s state of incorporation?
Roivant Sciences Ltd. is incorporated in Bermuda.
What is the Commission File Number for Roivant Sciences Ltd.?
The Commission File Number for Roivant Sciences Ltd. is 001-40782.
Filing Stats: 664 words · 3 min read · ~2 pages · Grade level 9 · Accepted 2025-09-03 13:38:54
Key Financial Figures
- $0.0000000341740141 — nge on which registered Common Shares, $0.0000000341740141 per share ROIV The Nasdaq Global Se
Filing Documents
- ef20055076_8k.htm (8-K) — 28KB
- ef20055076_ex99-1.htm (EX-99.1) — 26KB
- ef20055076_ex99-2.htm (EX-99.2) — 52KB
- image00001.jpg (GRAPHIC) — 85KB
- image00002.jpg (GRAPHIC) — 228KB
- image00003.jpg (GRAPHIC) — 96KB
- image00004.jpg (GRAPHIC) — 66KB
- image00005.jpg (GRAPHIC) — 101KB
- image00006.jpg (GRAPHIC) — 107KB
- image00007.jpg (GRAPHIC) — 106KB
- image00008.jpg (GRAPHIC) — 111KB
- image00009.jpg (GRAPHIC) — 66KB
- image00010.jpg (GRAPHIC) — 117KB
- image00011.jpg (GRAPHIC) — 68KB
- image00012.jpg (GRAPHIC) — 100KB
- image00013.jpg (GRAPHIC) — 78KB
- image00016.jpg (GRAPHIC) — 70KB
- image00017.jpg (GRAPHIC) — 87KB
- image00018.jpg (GRAPHIC) — 101KB
- image00019.jpg (GRAPHIC) — 108KB
- image00020.jpg (GRAPHIC) — 60KB
- image00021.jpg (GRAPHIC) — 79KB
- image00022.jpg (GRAPHIC) — 74KB
- image00023.jpg (GRAPHIC) — 103KB
- image00024.jpg (GRAPHIC) — 121KB
- image00025.jpg (GRAPHIC) — 100KB
- 0001140361-25-033767.txt ( ) — 3328KB
- roiv-20250903.xsd (EX-101.SCH) — 4KB
- roiv-20250903_lab.xml (EX-101.LAB) — 21KB
- roiv-20250903_pre.xml (EX-101.PRE) — 16KB
- ef20055076_8k_htm.xml (XML) — 4KB
01
Item 7.01. Regulation FD Disclosure. On September 3, 2025, Roivant Sciences Ltd. (the "Company") issued a press release providing an update on the Graves' Disease ("GD") development program at its subsidiary, Immunovant, Inc. ("Immunovant"). A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, or the Exchange Act, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, or the Securities Act. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the U.S. Securities Exchange Commission, or the SEC, made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
01
Item 8.01. Other Events. On September 3, 2025, the Company posted a presentation regarding the update on Immunovant's GD proof-of-concept study on the "Events & Presentations" page of its investor relations website at https://investor.roivant.com and will host a conference call and webcast to discuss the remission data from Immunovant's GD trial at 4:30 p.m. E.D.T. A copy of the presentation to be used by the Company during the conference call is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. The contents of the Company's website referenced in this Current Report on Form 8-K are not incorporated into this Current Report on Form 8-K.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description of Exhibit 99.1 Press Release, dated September 3, 2025. 99.2 Presentation, dated September 3, 2025. 104 Cover Page Interactive Data File (embedded with Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ROIVANT SCIENCES LTD. By: /s/ Keyur Parekh Name: Keyur Parekh Title: Authorized Signatory Dated: September 3, 2025